**Introduction to Pharmacology and Pharmacodynamics**

**Dr. Ramesh Kr. Gupta*a*, Kislaya Mishra*b***

*aAmity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector- 125, Noida-201313, India*

*bDepartment of Pharmacology, Hygia Institute of Pharmaceutical Education and Research, Lucknow-226020, Uttar Pradesh, India*

**Author for correspondence\***

**Dr. Ramesh Kr. Gupta**

Department of Pharmacology,

Amity Institute of Pharmacy,

Lucknow-206010, Uttar Pradesh, India

Email: [rkgupta@lko.amity.edu](mailto:rkgupta@lko.amity.edu)

Mob: +91 9451529612

**Abstract**

To comprehend and anticipate the pharmacologic behavior of drugs, it is essential to quantify the time course of pharmacodynamic responses with respect to plasma drug concentrations. The choice of an appropriate model should, whenever possible, be based on the drug's mode of action as well as other components of biological processes. Additionally, one advantage of mechanism-based physiologic models is their ability to calculate unavailable pharmacodynamics stages and parameters. Drug adverse effects that are reversible can be roughly classified into direct and indirect reactions. In view of these facts, this chapter covers the key pharmacodynamic principles, such as drug receptor interaction, the molecular mechanisms behind pharmacological activity, and dose guidelines.

**Keywords:** Pharmacodynamics; Drug receptor interaction; Molecular mechanisms; Indirect response models

**1. Introduction**

Pharmacodynamics is the study of a drug's molecular, biochemical, and physiological effects or actions. Its root words are "Pharmakon," which is Greek for "drug," and "Dynamikos," which is Greek for "power." All medications work by interacting with biological targets or structures that alter the functionality of the target molecule with respect to upcoming intermolecular interactions [1]. These interactions include receptor binding, chemical interactions, and effects after the receptor. One of the essential tenets of pharmacology is that for a pharmacological response to occur, drug molecules must chemically interact with one or more cell components. In other words, the function of these fundamental biological molecules must be altered by the chemical interactions between drug molecules and them[2]. The likelihood of a drug molecule interacting with a particular class of cellular molecule would be incredibly low if the drug molecules were just spread at random because there are obviously far more molecules in an organism than there are medication molecules. Therefore, pharmacological effects need the non-uniform distribution of the drug molecule inside the body or tissue, which is the same as saying that drug molecules must be "bound" to certain components of cells and tissues to produce a pharmacological effect [3].

***1.1 Protein targets for drug action***

Receptors, enzymes, carrier molecules (transporters), and ion channels, the four major subtypes of regulatory proteins, are usually chosen as the main therapeutic targets. Many drugs also attach to tissue proteins other than their primary targets, such as plasma proteins, with no obvious physiological effect. The broad statement that most drugs affect one or more of the four protein types mentioned above remains a reasonable place to start. Sometime the term "drug targets" is used to describe these important binding locations. Pharmacological research is primarily focused on the mechanism by which a drug molecule interacts with its target and triggers a physiological response. Protein molecules are the main targets of drugs. Even general anesthetics, which were once believed to interact with membrane lipids, now mostly appear to interact with membrane proteins. Every rule has an exception, as demonstrated by the numerous antibacterial, anticancer, mutagenic, and carcinogenic compounds that interact with DNA rather than proteins. In the same way that rat poison is poisonous to osteoclasts, bisphosphonates, which are used to treat osteoporosis, bind to calcium salts in the bone matrix. Nucleic acids, proteins, and antibodies are examples of the biopharmaceutical drugs of the new generation that are an exception. To coordinate the activity of their cells and organs, all multicellular organisms require a system of chemical communication, and receptors are an essential component of this system. Without them, we wouldn't be able to function. A few essential traits of receptors are illustrated by the impact of adrenaline (epinephrine) on the heart. The first protein to which adrenaline binds is the 1 adrenoceptor, which serves as a recognition site for adrenaline and other catecholamines. As it binds to the receptor, the heartbeat intensifies and accelerates, setting off a series of actions. When no adrenaline is available, the receptor frequently operates silently. The drug-target interaction that takes place downstream causes effects, which can be measured using biochemical or clinical techniques. Examples of this include the inhibition of platelet aggregation after aspirin administration, the lowering of blood pressure after ACE inhibitors delivery, and the role of insulin in lowering blood glucose. The administration of the drugs in the above examples may seem obvious, but it's crucial to remember that practitioners use the pharmacodynamic effects of these drugs rather than those that inhibit platelet aggregation, lower blood pressure, or lower blood glucose to reduce the risks of cerebrovascular accident, myocardial infarction, renal complications, and eye complications [4]. Medical professionals must always prioritize the patient over the symptom or the lab result. The two subfields of pharmacology are pharmacodynamics and pharmacokinetics, with pharmacodynamics focusing on how drugs interact with organisms and pharmacokinetics investigating this interaction.

***1.2 Pharmacodynamics actions***

Examples of pharmacodynamic activities include the following:

a) Indirectly inhibiting a receptor and its actions to stimulate activity.

b) Depressive activity mediated by direct receptor blockage and related side effects.

c) Direct chemical reactions, which can be both beneficial for therapy and undesired.

d) Binding to a receptor and suppressing it by preventing activation.

f) Stabilizing action, where the medication doesn't seem to work as either an agonist or an antagonist.

f) Each of these components has the potential to have both beneficial and unfavorable effects.

**2. Receptor interactions with drugs**

It may or may not happen that a drug molecule occupies a receptor before activating it. The term "activation" refers to the effect that the connected chemical has on the receptor, which alters how the cell behaves and results in a tissue reaction. Binding and activation are two distinct steps that take place when an agonist causes the receptor-mediated response. If a chemical binds to a receptor without activating it in order to prevent the binding of the agonist, that substance is referred to as a receptor antagonist. The frequency with which a drug binds to receptors is determined by its affinity, whereas the likelihood that the medication will activate the receptor once bound is determined by its efficacy. High potency drugs typically bind to receptors with high affinity, taking up a sizable fraction of the receptors even at low concentrations. In contrast to antagonists, who in the simplest scenario have no efficacy, agonists also have high efficacy. Drugs with intermediate degrees of activity are referred to as partial agonists to distinguish them from full agonists, whose efficacy is sufficient to elicit a maximal tissue response. The tissue response is still submaximal even though 100% of the receptors are occupied. Even though these concepts drastically oversimplify chemical processes, they still provide a helpful framework for addressing the effects of medications.

***2.1. Partial agonists and the concept of efficacy***

Drugs have only been thought of as either agonists or antagonists thus far. Agonists do not activate the receptor in any way when they occupy it. The efficacy of a pharmacological molecule, or its capacity to activate the receptor, is a graded feature as opposed to an all-or-nothing one. The biggest response that can be achieved varies from drug to drug when a series of chemically related agonist medicines that act on the same receptors is tested on a specific biological system. Some substances (referred to as complete agonists) can trigger the tissue's maximum reaction, while others (known as partial agonists) can only trigger a submaximal response. Following points needs to be remembered.

* + - 1. Drugs acting on receptors may be agonists or antagonists.

1. While antagonists bind to receptors without causing changes in cell function, agonists start such changes and result in consequences of various kinds.
2. The ability of an agonist to cause changes that result in consequences depends on two factors: effectiveness and affinity (i.e., the propensity to bind to receptors). Efficacy for antagonists is nil.
3. Partial agonists, which can only cause submaximal effects, have intermediate efficacy compared to full agonists, which can produce maximal effects.
4. In accordance with the two-state concept, efficacy reflects the substance's relative affinity for the receptor's resting and active states. In contrast to antagonists, agonists display selectivity for the active state. Although useful, this model is unable to capture the complexity of agonist activity.
5. Inverse agonists exhibit selectivity for the receptor's resting state; however, this is only significant when the receptors exhibit constitutive activity.
6. Allosteric modulators can change the action of an agonist by attaching to locations on the receptor other than the agonist binding site.

**3. Molecular basis of drug action**

Drugs interact with biological targets in order to have the desired effects, but the rate of action is influenced by the metabolic pathway and mechanism of the target. Direct, indirect, immediate, and delayed effects are among the various effect categories. Drug interactions with a receptor or enzyme frequently result in direct effects. Beta-blockers prevent the direct regulation of cAMP levels in the vasculature by smooth muscle cell receptors. When drugs interact with receptors and proteins or other biologic structures that ultimately results in the drug impact, this is known as an indirect effect. Nuclear transcription factors that the cell's cytoplasm binds to the nucleus and prevent DNA from being transcribed into mRNA, which creates various inflammatory proteins. Normal order is for immediate effects to follow direct pharmacological actions. Succinylcholine, which is composed of two acetylcholine (ACh) molecules joined end to end by their acetyl groups, interacts with the nicotinic acetylcholine receptor (nAChR) on skeletal muscle cells to impede neuromuscular transmission[5]. As a result of the channel remaining open, the membrane depolarizes, an action potential is generated, muscles contract, and 60 seconds after delivery, paralysis sets in. Before any delayed effects, there may be immediate side effects from the medicine. Patients with acute myeloid leukemia who receive chemotherapy medicines such cytosine arabinoside, which blocks DNA synthesis, develop bone marrow suppression days after treatment.

***3.1 Receptors***

The numerous hormones, transmitters, and other mediators discussed in Section 2 of this book serve as chemical messengers, serving as the sensing elements in a network of chemical communications that coordinates the function and responses of all the various cells in the body. Many drugs with therapeutic effect work as agonists or antagonists on known endogenous mediator receptors. The bulk of the time, the endogenous mediator was identified years before the receptor was pharmacologically and biochemically defined. For some receptors, like the cannabinoid and opioid receptors, endogenous mediators were subsequently discovered; however, the mediator, if any, is still unknown for other receptors, known as orphan receptors (see later). The host defense system additionally employs a class of receptors known as "Toll" receptors, which are adept at recognizing fragments of "foreign" bacteria and other invasive species.

***3.2 Ion channels***

Ion channels are essentially gateways in the cell membrane that only allow certain ions to pass through. They can be stimulated to open or close in a variety of ways. There are two important types: ligand- and voltage-gated channels. The former is accurately characterized as receptors since they only open when one or more agonist molecules are attached and agonist binding is necessary for their activation. Voltage-gated channels are opened by alterations in the transmembrane potential as opposed to agonist binding. Medication side effects can generally be classified into the following categories: 1. The drug molecule physically blocks the channel by attaching to the channel protein, either at the ligand-binding (orthostatic) site of ligand-gated channels or at alternative (allosteric) locations, as shown by the action of local anesthetics on the voltage-gated sodium channel. A drug that binds to allosteric sites on the channel protein and changes channel gating is benzodiazepines. These drugs bind to a location on the GABAA receptor-chloride channel complex (a ligand-gated channel) that is distinct from the GABA binding site, assisting the inhibitory neurotransmitter GABA in opening the channel. Dihydropyridine-type vasodilators that prevent L-type calcium channels from opening.

***3.3 Enzymes***

Numerous drugs target enzymes. For example, captopril inhibits angiotensin-converting enzyme; in other cases, the binding is irreversible and non-competitive (for example, aspirin inhibits cyclooxygenase). In many cases, the drug molecule is an analogue of the enzyme's substrate that inhibits it competitively. Drugs may also act as "false substrates," in which case the drug molecule undergoes a chemical transformation to produce an abnormal byproduct that obstructs the normal metabolic pathway. For instance, fluorouracil, an anticancer drug, cannot be converted into thymidylate, which prevents DNA synthesis, stops cell division, and replaces uracil as an intermediary in purine biosynthesis. It's also important to keep in mind that some drugs must undergo enzymatic degradation in order to turn from an inactive form, known as a prodrug, to an active form (for example, esterases convert the drug enalapril into enalaprilate, which inhibits the angiotensin-converting enzyme) [6]. In addition, drug toxicity frequently results from the enzymatic conversion of the drug molecule into a reactive metabolite. The liver is harmed in this manner by paracetamol. This undesirable side effect has a large practical impact despite having little to do with the drug's intended function.

***3.4 Transporters***

Ions and small polar chemical molecules often pass across cell membranes either through channels or with the help of a transport protein because penetrating molecules are frequently too lipid-soluble to do soon their own. There are numerous such transporters; examples of pharmacological significance include those in charge of transporting ions and a variety of organic molecules through the blood-brain barrier, intestinal epithelium, and renal tubule, moving Na+ and Ca2+ out of cells, transporting drug molecules, and more. Transporters will occur frequently in later chapters. The hydrolysis of ATP frequently provides the energy for the movement of molecules across their electrochemical gradient.

Because they feature a characteristic ATP binding site, these transport proteins are referred to as ABC (ATP-Binding Cassette) transporters. Two notable examples are the sodium pump (Na+-K+-ATPase) and multidrug resistance (MDR) transporters, which release fatal drugs from malignant and microbial cells and confer resistance to these therapeutic medicines. As a result of the coupling between the transport of organic molecules and the transport of ions (typically Na+), either in the same direction (symport) or the opposite direction (antiport), other situations, such as the neurotransmitter transporters, rely on the electrochemical gradient for Na+ produced by the ATP-driven sodium pump. Cocaine, for example, blocks the uptake of monoamine neurotransmitters into nerve terminals because it has a recognition site that makes the carrier proteins specialized for a certain penetrating species. Drugs that disrupt the transport mechanism can also target these recognition sites. The significance of transporters as a source of individual variation in the pharmacokinetic characteristics of many medications is becoming more widely recognized.

**4. Dosing Principles-Based Upon Pharmacodynamics**

There is a two-step decision-making procedure in therapeutics. To treat the illness process, a suitable medication must first be selected. Second, the appropriate dosage of the medication must be given to have the desired impact on the disease. To determine the ideal dose for a patient, the target approach combines pharmacokinetics (PK) and pharmacodynamics (PD). The goal effect for the patient should be determined when a medication has been selected to provide the appropriate clinical response. Target effect selection always involves striking a balance between therapeutic benefit and toxicity, which calls for clinical judgement in addition to in-depth knowledge of the drug's qualities. Once the desired outcome has been identified, reasonable dose prediction based on PD and PK knowledge can then be carried out. Further, a pharmacodynamic model defines the relationship between concentration and all pharmacological effects. The Emax model (Equation 1), which is the most popular, is defined by the maximum response, Emax, and the concentration that produces Emax at 50% of its maximum, C50 [7].

Effect = Emax X Concentration / C50 + Concentration Equation 1.

To determine the target concentration needed to provide the desired effect, the Emax model can be reconfigured (Equation 2).

Target Concentration = Target Effect X C50 / Emax-Target Effect Equation 2.

With the target concentration known, it is easy to anticipate the loading dosage (Equation 3) to attain the target concentration and the maintenance dose rate (Equation 4) to maintain the effect [8].

Target Loading Dose = Target Concentration × Volume of Distribution Equation 3.

Target Maintenance Dose Rate = Target Concentration × Clearance Equation 4.

Additional pharmacodynamics ideas include Kd: Both the drug's concentration at the receptor site and how strongly it binds to its target determine the pharmacologic response. Kd is a metric for how firmly a medication binds to a receptor. The ratio of the drug's attachment and dissociation rate constants to and from the receptors is known as Kd. At equilibrium, the rate of creation of the receptor-drug complex equals the rate of dissociation into the receptor and drug components. An equilibrium or affinity constant (1/Kd) can be determined by measuring the reaction rate constants. The higher the antibody's affinity for its target, the lower the Kd value should be. For the beta-2 receptor, albuterol, for instance, has a Kd of 100 nanomolar (nM) [7,8].

***4.1 Occupancy of Receptors***

According to the rule of mass action, the pharmacodynamics response increases when more receptors are occupied by the drug, albeit not all receptors must be engaged to achieve the maximum response. This idea, known as the concept of spare receptors, frequently refers to steroid receptors, catecholamine receptors, and the muscarinic and nicotinic acetylcholine receptors.

***4.2 Receptor Up- and Downregulation***

A prolonged antagonist exposure usually results in receptor upregulation, or an increased number of receptors, whereas a chronic agonist exposure usually results in receptor downregulation, or a lower number of receptors. Without changing the number of receptors on the cell membrane, additional mechanisms involving the modification of downstream receptor signalling may also be implicated in up- or downmodulation. As a result of prolonged insulin exposure, the insulin receptor is downregulated. Increased hormone binding causes receptor internalisation and degradation, which leads to a steady decrease in the number of insulin surface receptors [9]. Despite nicotine being an agonist, the nicotine receptor is an exception to the rule since it shows upregulation in receptor numbers after prolonged treatment, which explains some of the differences.

***4.3 Clinical Significance***

It is possible to apply the ideas of Kd, receptor occupancy, and up/downregulation to explain several dosing-related issues. Tolerance, which occurs when the effects of the drug seem to diminish with repeated dosages, is usually the outcome of long-term opioid use. When opioid receptors are activated, the production of intracellular proteins called arrestins is stimulated [10]. Arrestins bind to the intracellular portion of the opioid receptor, block G-protein signalling, and endocytose the receptor. This results in less "signalling" or tolerance. Arrestin activity is one of the several pathways that cause receptor down-regulation and receptor tolerance [11]. In the context of pharmacological therapy, it should go without saying that the objective of pharmacodynamics is to exert favourable effects at the lowest dose required to produce the most therapeutic benefit while minimising the pharmacodynamics that leads to an adverse event [12]. Every member of the multidisciplinary healthcare team who prescribe, doses, dispenses, or delivers pharmacological therapy must be familiar with the fundamentals of pharmacodynamics and pharmacokinetics. It should go without saying that knowledge must correspond to the therapeutic role of the practitioner.

**5. Conclusion**

In conclusion, it is hoped that an improved understanding of the clinical pharmacology of medications will enhance the treatment of disease patients. Clinicians should, at the very least, be aware of the fundamental ideas and the limitations of the current approaches. Optimizing the use of combination therapy is the next challenge. Evaluation of the pharmacodynamics of drug combinations will be possible once studies on the pharmacodynamics of single drugs are completed.

**References:**

[1] Mager, D.E, Woo, S. & Jusko, W.J (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans Drug Metab Pharmacokinet. 24(1): 16-24  <https://pubmed.ncbi.nlm.nih.gov/19252333/>

[2] IUPhar Pharmacology Education Project (Website) Clinical pharmacodynamics [www.pharmacologyeducation.org/.../clinical-pharmacodynamics](http://www.pharmacologyeducation.org/clinical-pharmacology/clinical-pharmacodynamics).

[3] Ashp.org (Website) Lesson 1: Introduction to Pharmacokinetics and Pharmacodynamics. <https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf>

[4] Cirillo P, Taglialatela V, Pellegrino G, Morello A, Conte S, Di Serafino L, Cimmino G. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis. 2020 Aug;50(2):468-472.

[5] Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI. Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33.

[6] Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757-760.

[7] Keller F, Hann A. Clinical Pharmacodynamics: Principles of Drug Response and Alterations in Kidney Disease. Clin J Am Soc Nephrol. 2018 Sep 07;13(9):1413-1420.

[8] Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008 Dec;22(6):633-48.

[9] Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016 Feb;42(1):15-31.

[10] Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J. 2008 Dec;10(4):537-51.

[11] Lees P, Cunningham FM, Elliott J. Principles of pharmacodynamics and their applications in veterinary pharmacology. J Vet Pharmacol Ther. 2004 Dec;27(6):397-414.

[12] Cahill CM, Walwyn W, Taylor AMW, Pradhan AAA, Evans CJ. Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation. Trends Pharmacol Sci. 2016 Nov;37(11):963-976